Brolucizumab Preserves Vision Better Than Laser in Diabetic Retinopathy

Proliferative diabetic retinopathy remains a leading cause of legal blindness among working-age adults, characterized by pathological neovascularization (the growth of abnormal new blood vessels) that can lead to vitreous hemorrhage and tractional retinal detachment [1]. For decades, panretinal photocoagulation (a laser treatment that ablates peripheral retinal tissue to reduce oxygen demand) has served as the definitive therapy, though it often results in permanent visual field constriction [2, 3]. While intravitreal inhibitors of vascular endothelial growth factor (a protein that stimulates blood vessel growth) have emerged as potent alternatives that can regress neovascularization without tissue destruction, the necessity for frequent injections remains a significant clinical hurdle [4, 5]. Furthermore, the introduction of high-potency agents has raised specific safety concerns regarding intraocular inflammation and retinal vasculitis (inflammation of the retinal blood vessels) [6, 7]. A new study now offers fresh insights into the comparative efficacy and safety of a specific anti-vascular endothelial growth factor dosing regimen versus traditional laser therapy.